Pharma Majors with US Facilities: Context of US Tariffs

​Pharma Majors with US Facilities: Context of US Tariffs

​The companies with crucial advantage in the "Make in America" tariff environment.

​Companies with Strongest Manufacturing Footprint (Highest Mitigation Potential):

  • ​Cipla: Leads the list with 5 US Manufacturing facilities and 2 R&D units (New York, Massachusetts). This is the strongest existing local production capacity, making it the best positioned to shift production and mitigate the impact of the new import tariffs.
  • ​Aurobindo: Has a significant presence with 4 US Manufacturing facilities and 4 R&D units (New Jersey, North Carolina, New York). Its extensive facilities provide a robust base to ramp up local production.
  • ​Piramal Pharma: Possesses 4 US Manufacturing facilities (Delaware, Kentucky, Michigan, Pennsylvania). This footprint, likely supporting its contract manufacturing business (CDMO), offers strategic flexibility for increasing US-based production.
  • ​Sun Pharma: Operates 3 US Manufacturing facilities (New Jersey, Massachusetts, Tennessee). While a large portion of its specialty products are currently imported, these existing plants are critical assets for expansion and tariff circumvention.

​Companies with Existing but Smaller Manufacturing Footprint (Moderate Mitigation Potential):

  • ​Alkem Lab, Biocon API, Dr Reddy's Lab, Glenmark, Ipca Lab, and Lupin: Each of these companies lists 1 US Manufacturing facility.
    • ​This single manufacturing base is a key advantage over companies with no production units. It provides an immediate physical presence that can potentially be expanded or used to qualify as "under construction" for the tariff exemption.
    • ​Dr Reddy's Lab is noted to have a large share of its US-bound products manufactured in India, meaning its single US plant insulates only a small portion of its revenue, leaving the rest vulnerable.

​Company Highly Vulnerable (No Listed Manufacturing):

  • ​Zydus: This company is listed with 1 US R&D facility but no US Manufacturing facility.
    • ​Since the tariff exemption is tied to manufacturing facilities that are being built, Zydus's US exports are potentially the most exposed to the full 100% tariff.
    • ​To avoid the duty, Zydus would need to urgently "break ground" on a new manufacturing plant in the US.

Comments

Post a Comment

Popular posts from this blog

An easy plan to finance graduation and higher education of low income muslim students

Image
  Proposal for Muslim Children in India (Sharia-Compliant Model) to create a corpus of 3-4 lakh. Let's study how the US “Trump Accounts” + Dell Family Gift Help Children Through Compounding The new US programme—popularly called “Trump Accounts” —creates small, long-term investment accounts for children. Every eligible child receives $1,000 from the US Treasury , and with Michael & Susan Dell’s additional pledge, another $250 for children under age 10. The key idea is simple: Start early → Invest consistently → Let compounding work for decades. Michael and Susan Dell are one of America’s most prominent business families. Michael Dell founded Dell Technologies , one of the world’s largest computer companies, starting it from his college dorm room. Together, the Dell family has spent decades funding education, children’s health, and opportunity-building programs globally. Their $6.25 billion gift is one of the largest in modern US history dedicated to children. But the rea...
Read more

Nifty 50 and Sensex Targets for the Next 3–5 Years (2026–2030) and sector insights.

Nifty 50 and Sensex Targets for the Next 3–5 Years (2026–2030). Sector-wise insights added.  As of November 23, 2025, India's benchmark indices—Nifty 50 and BSE Sensex—have experienced volatility this year, with the Nifty closing around 24,800–25,000 and the Sensex near 82,000–83,000, down from September peaks amid FII outflows and global uncertainties. Reputable institutions like Goldman Sachs, Morgan Stanley, ICICI Direct, Motilal Oswal, Jefferies, Citi, and HSBC have issued updated forecasts, driven by expectations of 13–19% annual earnings growth (FY26–28), GDP expansion to 7%, reflationary policies, and domestic inflows absorbing supply pressures. These projections assume stable macros (e.g., oil below $80/barrel, RBI rate cuts) but note risks like US recession or trade tensions. Longer-term targets (beyond 2026) are scarcer and more optimistic, often from Indian brokerages, projecting 12–15% CAGR based on structural reforms and $5–6 trillion GDP by 2030. Below is a summary ...
Read more

How to categorize Large, Mid, and Small-Cap stocks

  Large-Cap : Ranking:  Top 100 companies by market cap. Market Cap (Approx):  Over ₹20,000 Crore (or higher, depending on market). Characteristics:  Well-established, stable, lower risk, often "blue-chip" stocks, steady returns. Mid-Cap : Ranking:  Companies ranked 101st to 250th by market cap. Market Cap (Approx):  Between ₹5,000 Cr and ₹20,000 Cr. Characteristics:  Higher growth potential than large-caps, moderate risk, "rising stars". Small-Cap : Ranking:  Companies ranked 251st and beyond by market cap. Market Cap (Approx):  Below ₹5,000 Crore (or lower). Characteristics:  High risk, high reward, early growth stage, volatile, best for aggressive investors.   Ref https://support.zerodha.com/category/trading-and-markets/trading-faqs/trading-categories-and-groups/articles/large-mid-and-small-cap
Read more